Thursday, August 28, 2025
StockstToday.com Logo
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings
No Result
View All Result
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analysts Provide Mixed Ratings and Price Targets for Cooper Companies

Elaine Mendonca by Elaine Mendonca
January 12, 2024
in Breaking News
0
Finance_Financialization
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

As of January 12, 2024, analysts have provided a range of opinions on Cooper Companies (NASDAQ: COO), with a total of 4 analysts giving their ratings. Among these ratings, 1 analyst is bullish, 1 is somewhat bullish, and 2 are indifferent, while none are somewhat bearish or bearish.

Looking at the 12-month price targets, the average target stands at $387.5, with a high estimate of $440.00 and a low estimate of $355.00. This average target represents a 5.1% decrease compared to the previous average price target of $408.33. Notable recent actions by analysts include Jason Bednar from Piper Sandler raising the overweight rating to $440.00, Patrick Wood from Morgan Stanley lowering the equal-weight rating to $355.00, Robbie Marcus from JP Morgan lowering the neutral rating to $375.00, and Craig Bijou from B of A Securities announcing a buy rating with a price target of $380.00.

Based on the current 3 hold ratings, the consensus rating for Cooper Companies stock is a moderate buy. Analysts predict a potential upside of 14.61% for Cooper Companies’ stock based on their 12-month stock forecasts.

Furthermore, the average twelve-month price prediction for Cooper Companies is $400.30, suggesting a potential upside of 9.5% from the stock’s current price.

COO Stock Shows Strong Performance: Trading Near 52-Week High and Above 200-Day Moving Average

COO stock showcased a strong performance on January 12, 2024, trading near the top of its 52-week range and above its 200-day simple moving average. According to data from CNN Money, the price of COO shares increased by $3.24 since the market last closed, representing a rise of 0.85%. The stock closed at $383.77, indicating a significant upward movement. One notable aspect of COO stock’s performance is that it remained unchanged in after-hours trading, suggesting that investors are maintaining their confidence in the stock even after the market has closed. Trading near the top of its 52-week range and above its 200-day simple moving average are positive indicators for the stock’s future performance. However, investors should always conduct thorough research and analysis before making any investment decisions.

COO Stock Performance on January 12, 2024: Total Revenue, Net Income, and EPS Analysis

Title: COO Stock Performance on January 12, 2024

Introduction:
On January 12, 2024, the stock performance of COO, a leading company in the healthcare industry, was under scrutiny. This article will delve into the financial data available from CNN Money, focusing on the company’s total revenue, net income, and earnings per share (EPS) for the past year and the fourth quarter. By analyzing these figures, we aim to provide a comprehensive overview of COO’s stock performance on that particular day.

Total Revenue:
COO’s total revenue for the past year stood at $3.59 billion, marking an increase of 8.61% compared to the previous year. However, the total revenue remained flat since the previous quarter, with Q4 revenue recorded at $927.10 million.

Net Income:
COO’s net income for the past year amounted to $294.20 million, indicating a decrease of 23.74% compared to the previous year. Similar to the total revenue, the net income remained flat since the previous quarter, with Q4 net income reported at $84.50 million.

Earnings Per Share (EPS):
COO’s earnings per share (EPS) for the past year stood at $5.91, reflecting a decrease of 23.9% compared to the previous year. Similar to the net income and total revenue, the EPS held flat since the previous quarter, with Q4 EPS reported at $1.69.

Stock Performance:
Based on the provided financial data, COO’s stock performance on January 12, 2024, may have been influenced by various factors. While the company experienced growth in total revenue over the past year, the decline in net income and EPS may have impacted investor sentiment. The flat performance since the previous quarter indicates stability but lacks any significant positive momentum.

Conclusion:
COO’s stock performance on January 12, 2024, was characterized by growth in total revenue over the past year, albeit with no significant changes in the fourth quarter. However, the decline in net income and EPS throughout the year may have raised concerns among investors. It is crucial for investors to consider these financial indicators when assessing a company’s stock performance, as they provide insights into its profitability and overall financial health.

Tags: COO
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Home Construction Stock Exchange

CRH Inc Potential Undervaluation in the Construction Materials Industry

Technology Robotics Stock Market Today

Analysts Maintain Neutral Rating on Zoom Video Communications with Varying Price Targets

Automotive Stock Market Today

Stellantis Overcomes Supply Disruptions with Airfreight Solution

Recommended

Norfolk Southern Stock

Norfolk Southern Stock Gains Analyst Confidence Amid Operational Challenges

1 week ago
Alibaba Stock

Alibaba Shares Face Headwinds Ahead of Quarterly Earnings Release

1 week ago
CarGurus Stock

CarGurus Shares Surge as Q2 Earnings Exceed Market Expectations

1 week ago

Title Cullinan Oncology Receives FDA Approval for Groundbreaking Cancer Therapy with CLN619 Antibody

1 year ago

Categories

  • Analyst Ratings
  • Breaking News
  • Business & Industry Trends
  • Commodities
  • Cryptocurrency
  • ETF
  • Index
  • Market News
  • Stock Picks
  • Stock Targets
  • Stocks
  • Uncategorized

Topics

AAL AAPL ABNB Adobe ADSK AMD AMZN Apple AVGO BA Broadcom C Coinbase COST CRWD DELL DIS DWAC Eli Lilly GM IBM INTC Intel LLY META Micron MP Materials MSFT NFLX NIO NVO Opendoor Oracle Palantir PARA PLTR Red Cat Robinhood Rocket Lab USA SMCI Strategy Tesla TGT Tilray TSLA
No Result
View All Result

Highlights

Suzano’s Strategic Shift Yields Impressive Financial Turnaround

Wall Street Analysts Boost Price Targets for Xometry Following Strong Quarterly Results

Brightspire Capital: A Study in Contradictory Financial Signals

NuCana Shares Face Unrelenting Selloff as Technical Support Nears

Photronics Defies Industry Headwinds with Stellar Quarterly Performance

Institutional Investors Pile Into Solaris While Director Offloads Shares

Trending

LendingTree Stock
Stocks

LendingTree Shares Gain Momentum from Analyst Upgrade and Refinancing

by Robert Sasse
August 28, 2025
0

LendingTree is experiencing a notable surge driven by two significant developments: a substantial analyst rating upgrade and...

Palantir Stock

Palantir’s Market Rollercoaster: Valuation Concerns Clash With Record Performance

August 28, 2025
Intuitive Surgical Stock

Intuitive Surgical’s Workforce Reduction Sparks Investor Concern

August 28, 2025
Suzano Stock

Suzano’s Strategic Shift Yields Impressive Financial Turnaround

August 28, 2025
Xometry Stock

Wall Street Analysts Boost Price Targets for Xometry Following Strong Quarterly Results

August 28, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Recent News

  • LendingTree Shares Gain Momentum from Analyst Upgrade and Refinancing August 28, 2025
  • Palantir’s Market Rollercoaster: Valuation Concerns Clash With Record Performance August 28, 2025
  • Intuitive Surgical’s Workforce Reduction Sparks Investor Concern August 28, 2025

Categories

  • Analyst Ratings
  • Breaking News
  • Business & Industry Trends
  • Commodities
  • Cryptocurrency
  • ETF
  • Index
  • Market News
  • Stock Picks
  • Stock Targets
  • Stocks
  • Uncategorized

© 2024 Stocks Today

No Result
View All Result
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings

© 2023 StocksToday.com